Psychopharmacology · 2026
Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Savini Marisa J, King Kylie M, Puppel Lillianna P, Al-Olimat Aleece K, Molnar Noelle M, Schneider Evelynn J, Straub Savannah E, Parker Joe, Gottron Colin J, Bach Allison M, Lambdin Solomon M, Regan Stephanie M, Williams Kaitlyn E, Welker Troy R, Jones J Andrew, Zoladz Phillip R
Аннотация
RATIONALE: Psychedelics are considered to be promising therapeutic agents that could effectively treat several psychological disorders. However, these compounds can exert acute adverse effects that limit their practicality.
OBJECTIVES: Across three experiments, the present study examined the acute and delayed effects of psilocybin (PSIL) and its putatively non-hallucinogenic analog, norbaeocystin (NOR), on anxiety-like behavior and the influence of the female estrous cycle on acute response to the compounds.
METHODS: In Experiment 1, rats were treated with PSIL or NOR (0.3-1 mg/kg) and tested on the elevated plus maze (EPM) or open field 30 min later. In Experiment 2, male and female rats were treated with 1 mg/kg PSIL or NOR and tested on the EPM 24 h later. In Experiment 3, we tracked the female estrous cycle to determine whether it was associated with the acute effects of PSIL or NOR on EPM behavior and the acoustic startle response (ASR).
RESULTS: In Experiment 1, both PSIL and NOR exerted acute anxiogenic effects in males, while only the highest dose of PSIL increased anxiety-like behavior in females. In Experiment 2, neither PSIL nor NOR impacted EPM behavior the next day. In Experiment 3, PSIL, but not NOR, had acute anxiogenic effects on EPM behavior, effects that were independent of estrous stage. Females treated with PSIL during diestrus exhibited some signs of greater ASR habituation.
CONCLUSIONS: PSIL and NOR exerted transient dose- and sex-specific effects on anxiety-like behavior, which may inform their use as novel therapeutics.
OBJECTIVES: Across three experiments, the present study examined the acute and delayed effects of psilocybin (PSIL) and its putatively non-hallucinogenic analog, norbaeocystin (NOR), on anxiety-like behavior and the influence of the female estrous cycle on acute response to the compounds.
METHODS: In Experiment 1, rats were treated with PSIL or NOR (0.3-1 mg/kg) and tested on the elevated plus maze (EPM) or open field 30 min later. In Experiment 2, male and female rats were treated with 1 mg/kg PSIL or NOR and tested on the EPM 24 h later. In Experiment 3, we tracked the female estrous cycle to determine whether it was associated with the acute effects of PSIL or NOR on EPM behavior and the acoustic startle response (ASR).
RESULTS: In Experiment 1, both PSIL and NOR exerted acute anxiogenic effects in males, while only the highest dose of PSIL increased anxiety-like behavior in females. In Experiment 2, neither PSIL nor NOR impacted EPM behavior the next day. In Experiment 3, PSIL, but not NOR, had acute anxiogenic effects on EPM behavior, effects that were independent of estrous stage. Females treated with PSIL during diestrus exhibited some signs of greater ASR habituation.
CONCLUSIONS: PSIL and NOR exerted transient dose- and sex-specific effects on anxiety-like behavior, which may inform their use as novel therapeutics.